FDA panel narrowly backs unapproved peptide drugs favoured by RFK Jr and wellness influencers
A panel of federal health advisers recommended easing access to several unapproved peptides, with an 8-6 vote, despite safety concerns from FDA scientists. The decision, which is not binding, may empower Health Secretary Robert F Kennedy Jr. to challenge existing FDA restrictions. If the FDA adopts the panel's recommendation, telehealth companies are likely to increase marketing of these peptides for wellness and cosmetic purposes.